BFEC
ALXN

Benjamin F. Edwards & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,297
Closed -$238K – 1795
2021
Q2 		$238K Sell
1,297
-23
-2% -$3.95K 0.01% 610
2021
Q1 		$202K Sell
1,320
-63
-5% -$9.74K 0.01% 672
2020
Q4 		$216K Sell
1,383
-527
-28% -$67.7K 0.01% 621
2020
Q3 		$219K Buy
1,910
+183
+11% +$19.7K 0.01% 569
2020
Q2 		$194K Sell
1,727
-83
-5% -$8.81K 0.01% 583
2020
Q1 		$163K Sell
1,810
-1,039
-36% -$102K 0.01% 559
2019
Q4 		$308K Buy
2,849
+1,047
+58% +$112K 0.02% 499
2019
Q3 		$176K Buy
1,802
+902
+100% +$102K 0.01% 591
2019
Q2 		$118K Hold
900
– – 0.01% 662
2019
Q1 		$122K Buy
900
+200
+29% +$24.9K 0.01% 628
2018
Q4 		$68K Buy
+700
New +$82.7K 0.01% 759
2016
Q2 		– Sell
-83
Closed -$12K – 1144
2016
Q1 		$12K Hold
83
– – ﹤0.01% 779
2015
Q4 		$16K Hold
83
– – ﹤0.01% 747
2015
Q3 		$13K Sell
83
-36
-30% -$6.57K ﹤0.01% 819
2015
Q2 		$22K Buy
119
+55
+86% +$9.49K ﹤0.01% 764
2015
Q1 		$11K Buy
64
+41
+178% +$7.42K ﹤0.01% 882
2014
Q4 		$4K Hold
23
– – ﹤0.01% 925
2014
Q3 		$4K Hold
23
– – ﹤0.01% 891
2014
Q2 		$4K Buy
+23
New +$3.63K ﹤0.01% 849

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Benjamin F. Edwards & Company's ALXN Position: Q3 2021 in Review

Benjamin F. Edwards & Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,297 shares — an estimated $238K sold.

Benjamin F. Edwards & Company first reported a position in ALXN in Q2 2014 and held it in 19 quarters. The position peaked at $308K in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Benjamin F. Edwards & Company reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 1,297 Alexion Pharmaceuticals shares in Q3 2021, an estimated $238K.
  • Benjamin F. Edwards & Company first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 19 quarters.
  • Benjamin F. Edwards & Company's Alexion Pharmaceuticals position peaked at $308K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2021, filed 2 Nov 2021.